Cross-Sector entity
RadNet is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in health-it, which accounts for 1 of those 2, with the remainder spread across 1 other category. Timothy T. Goodnow appears in 2 tracked Cross-Sector stories from March 3, 2026.
2 verified stories tracked
Last mentioned: Mar 3, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
RadNet is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in health-it, which accounts for 1 of those 2, with the remainder spread across 1 other category. Timothy T. Goodnow appears in 2 tracked Cross-Sector stories from March 3, 2026. The tracked stories average 11 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Timothy T. Goodnow. Shared-story counts are live from our verified record — not editorial picks.
UroGen Pharma and Senseonics reported strong Q4 2025 results, driven by the successful commercial launches of Zasturi and Eversense 365. Both companies are navigating critical transitions—UroGen through new reimbursement codes and Senseonics by assuming full commercial control—positioning them for significant revenue scaling in 2026.
Healthcare technology and medical device leaders reported strong Q4 2025 results, characterized by aggressive AI acquisitions and successful transitions to direct commercial models. These shifts, led by RadNet and Senseonics, signal a maturing market for digital health platforms and long-term implantable technologies.
